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1. Introduction 
Primary or idiopathic focal and segmental glomerulosclerosis (FSGS) accounts for 
approximately 10% and 20% of cases of idiopathic nephrotic syndrome in children and 
adults, respectively. The primary pathophysiologic process appears to be an injury of 
glomerular visceral epithelial cells, so-called podocytes, followed by an initial proliferation 
of mesangial, epithelial and endothelial cells with subsequent collapse of glomerular 
capillary loops and eventual sclerosis. The most popular pathogenetic hypothesis suggests 
the involvement of one or more circulating plasma factor(s), that appears to be protein 
between 30 and 50 kD molecular weight, altering glomerular permeability to proteins and 
causing proteinuria. Familial forms of FSGS occur due to mutations of several podocyte 
protein genes. FSGS can be a secondary process as well. Regardless of the etiology, the 
natural history of the disease include: peripheral edema, refractory proteinuria, 
hypertension, and progressive loss of renal function. FSGS frequently recurs after kidney 
transplantation with the recurrence rate of 30% after first transplantation, and 80% or more 
in the subsequent transplants. Risk factors of recurrence include a rapid progression of the 
primary disease to chronic kidney disease (CKD) stage 5, younger recipient age, early onset 
of nephrotic range proteinuria after kidney transplantation and frequent loss of the first and 
subsequent allografts. Considerable number of patients with recurrent FSGS respond to 
plasmapheresis (PP), especially if instituted early in the course of disease and before 
glomerulosclerosis has been established. Combined therapy with PP and cyclophosphamide 
may be beneficial. Other treatments consists of intravenous cyclosporine (CsA) and oral 
steroids. In some patients successful treatment of recurrent FSGS with the anti-CD20 
monoclonal antibody, rituximab, in conjunction with PP has been reported.  As a 
symptomatic treatment the use of ACE inhibitors should be recommended.  
2. FSGS in native kidneys 
Focal segmental glomerulosclerosis (FSGS) first described by Arnold Rich in 1959 (1) is a 
clinicopathological entity, characterized by focal and segmental occurrence of lesions with 
mesangial sclerosis, obliteration of glomerular capillaries with hyalinosis and intracapillary 
foam cells, formation of adhesions between the glomerular tuft and Bowman’s capsule, and 
podocyte hypertrophy. Clinically FSGS is characterized by nephrotic syndrome (NS) and 
progressive loss of renal function. It is the most common histopathologic diagnosis 
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associated with idiopathic steroid-resistant NS in children, and one of the most frequent in 
adults, but in some patients, FSGS progress to CKD stage 5 without NS. Within 10 years of 
initial presentation, more than 50% of patients with FSGS develop CKD requiring renal 
replacement therapy (2). NAPRTCS 2007 Annual Report reveals that 14,3% of patients on 
dialysis and 11,4% of patients with renal transplant have FSGS as their primary diagnosis.  
2.1 Pathogenesis of FSGS in native kidneys 
The etiology of idiopathic FSGS and its post-transplant recurrence are still unclear; however, 
the recent studies on circulating permeability factor(s) (PF), genomics of podocin (NPHS2) 
and the emerging data on costimulatory molecules suggest an interplay of factors in 
different subgroups of patients with FSGS (3). Currently, FSGS is known to be due to an 
abnormality of the visceral epithelial cells (podocytes) of the glomerulus (4; 5). The 
morphological hallmark of primary FSGS is diffuse effacement of podocyte foot processes 
(usually > 80%), involving essentially all of the glomerular capillary loops. Damage of foot 
processes by the release of lymphokines/cytokines from T cells, possibly Th2 cells has been 
postulated (6). Transforming growth factor ǃ (TGFǃ) is probably a mediator of scarring by 
induction of apoptosis of podocytes and adherence of the parietal epithelial cells to the 
naked GBM. The familial, genetic forms of FSGS result from abnormalities in gene 
transcription controlling assembly of slit diaphragm, actin-based cytoskeleton, and adhesion 
complexes, which are essential for the podocyte function in maintaining an effective 
filtration barrier. Some of the gene mutations in patients with FSGS include podocin 
(NPHS2), nephrin (NPHS1), ǂ actinin-4 (ACTN-4), CD2-associated protein (CD2AP), WT1 
transient receptor potential cation 6 (TRPC6), and phospholipase ϵ C (PLCE1/NPHS3) (7). 
FSGS can also be a secondary process due to underlying conditions including obesity, HIV 
or parvovirus B19 infection, plasma cell proliferative disease, lithium or pamindronate 
treatment, urinary reflux, and heroin abuse. The amount of foot processes effacement in 
secondary FSGS (usually < 30%) can be used as a morphological clue to distinguish primary 
and secondary process. A decreased ratio of podocytes to the glomerular filtration surface 
area appears to be the leading mechanism of secondary FSGS (8). 
2.2 Role of permeability factor(s) or intrinsic podocyte defect 
The pathogenesis of FSGS is not fully clarified, but injury of podocytes is crucial. Shalhoub 
was the first to propose the presence of a circulating mediator secreted by T cells (9), named 
permeability factor  (PF) by Savin’s group with an anionic charge and affinity for protein A 
and galactose and low molecular weight (10; 11). Though several studies strongly suggest 
the importance of the T cell origin circulating PF, this factor has not been completely 
identified biochemically and may not be specific for FSGS (7). A putative PF of molecular 
weight between 30 and 50 kDa has been isolated from sera of patients with FSGS and 
increased glomerular permeability to albumin (Palb) in vitro (12). Permeability factor(s) may 
exert direct effects on the nephrin and podocin in the podocyte or may alter 
phosphorylation of cellular proteins in the podocyte, influence the activity of serine 
proteases or induce of integrin-like kinase activity that leads to detachment of podocyte 
from GBM (11;13; 14). This factor inhibits also the synthesis of nitric oxide, probably by up-
regulating asymmetric dimethyloarginine (ADMA) – an endogenous inhibitor of all nitric 
oxide synthases, with lose of anti-fibrotic effect in mesangium (15). Recently, McCarthy et al. 
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have identified a peptide – cardiotrophin-like cytokine 1 (CLC-1), which may be the 
presumed PF (16). Patients with a very high pretransplant level of PF had nearly 100% 
recurrence of their disease in the transplant kidney (12). Rarely PF may be present in 
patients with podocin (NPHS2) mutations. High pretransplant Palb was found in 5 children 
with autosomal recessive podocin mutations, in which FSGS recurred after transplantation 
in four out of five (17). Since the PF is mildly anionic, it is unlikely that the effect of this 
factor is to neutralize the anionic sites on the GBM. Recent studies have suggested that there 
may be plasma factors that inhibit the PF (18; 19; 20). Furthermore, the net effect of the 
increased permeability may result from the absence or loss of an inhibitor for PF (19; 20). 
These inhibitory serum factors may be normal serum components such as apolipoproteins E 
and J (20). Further studies found that urine of patients with FSGS neutralize the PF activity 
of the serum, suggesting loss of an inhibitor in the urine (21), that may play a central role in 
the process after kidney transplantation and possibly also in the original disease (17). These 
findings suggest the deficiency of an inhibitor to the normally occurring PF as a primary 
cause for proteinuria. Alterations in the integrins (ǂ3ǃ1) that are involved in the attachment 
of podocytes to the GBM might be important in some forms of FSGS (8). Novel pathway of 
injury in FSGS are probably CD80/86, transmembrane proteins normally expressed on the 
surface of B-cells and other antigen-presenting cells, that are important players of 
costimulation. Reiser et al. reported  the novel role of CD80 in podocytes as an inducible 
modifier of glomerular permselectivity (22).The knockout mice lacking CD80 were protected 
from lipopolysaccharide (LPS)-induced NS (22). In experimental model, LPS up-regulated 
CD80 expression on podocytes, resulting in rapid podocyte effacement and severe 
proteinuria. This link between an innate immune response and gene mutations regulating a 
slit-diaphragm components may represent a novel scheme for understanding the 
pathogenesis of recurrent FSGS in some patients (22). 
2.3 Role of gene mutations for proteins exclusively expressed by podocytes 
Recent studies on gene mutations encoding podocin and other components of slit-
diaphragm have underscored the heterogeneity of the idiopathic forms of FSGS. Alterations 
of the slit-diaphragm assembly can lead to changes in the selective barrier function, 
resulting in proteinuria. The discovery of gene mutations of the slit-diaphragm exclusive 
proteins in familial NS represented a breakthrough in the research of mechanisms of NS in 
humans. Mutations of NPHS2 gene (encoding for podocin and localized on chromosome 1q25-
31), are the most common cause of familial NS and sporadic inherited FSGS. Homozygous 
carriers of NPHS2 mutations develop massive proteinuria in early childhood, not responding 
to common therapies and progressing to CKD stage 5 (23; 24; 25). So, in children seek for 
podocin mutations is justified to avoid a useless prolonged course of corticosteroids because of 
steroid resistance. As a corollary, proteinuria should not recur in patients with NPHS2 
mutations because the molecular defect of podocin should be vanished. But the recurrence of 
the FSGS is observed also in these patients. The recurrence of proteinuria after renal 
transplantation in homozygous carriers of podocin mutations is associated with high values of 
permeability activity for albumin (Palb); which suggest a role of PF also in this inherited 
condition. Heterozygous carriers of NPHS2 mutations (including variants) present variable 
clinical phenotypes with later onset of proteinuria. Tsukaguchi et al. found that the R229Q 
heterozygous variant of NPHS2 (which is found in FSGS patients with the same frequency as 
in a normal population) appeared not to cause FSGS, but rather to enhance susceptibility to 
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FSGS in association with a second mutant NPHS2 allele (26). In authors material two out of 10 
patients with FSGS in native kidneys revealed R229Q heterozygous variant and only one of 
them experienced recurrence of FSGS during the first month after transplantation (27). 
3. FSGS recurrence after kidney transplantation 
Recurrent FSGS after renal transplantation was described by Hoyer et al. in 1972 (28). 
Nowadays FSGS is the most common kidney disease known to recur after kidney 
transplantation and only a small proportion being de novo. Recurrence rate of FSGS in 
pediatric patients is 50% and 30% in adults (29). A reliable estimate is approximately 30% to 
40% at a first graft, with an exponential increment of risk (up to 80%) at subsequent renal 
grafts (30; 31; 32; 33). Patients with recurrent FSGS have higher incidence of delayed graft 
function (DGF) and five-year graft loss rates 30-50% and up to 80% over a follow-up period 
of 10 years (27; 31; 34; 35; 36; 37). The most popular hypothesis suggests the involvement of 
one or more circulating PF altering renal permeability to proteins and causing proteinuria in 
allograft. According to this possibility, removal of the putative PF by plasmapheresis (PP) or 
selective procedures with protein A column associated with a course of immunosuppression 
would restore a good long-term outcome of the graft. Patients with high pretransplant Palb 
activity have a higher risk of FSGS recurrence (30). The impact of recipient age on FSGS 
recurrence was confirmed by Bertelli et al. in patients without mutation of podocin with 
early recurrence of proteinuria in 44% of younger patients and in 23% of the older ones (30). 
It is taken as a proof of the existence of circulating PF(s) that are also putative effectors of 
original proteinuria in these patients (30). 
3.1 FSGS recurrence in patients with NPHS2 mutation 
Patients with clearly two pathogenic NPHS2 mutations, although have early onset of NS in 
native kidneys, have a very low risk (about 3%) of FSGS recurrence after kidney 
transplantation compared with non-NPHS2 FSGS patients  (recurrence rate about 34%) (25; 
30; 38). On the other hand, simple heterozygous NPHS2 mutations have a similar high 
recurrence as the non-familial forms (29). Recurrence of proteinuria after kidney 
transplantation in patients with homozygous NPHS2 mutation is caused by other 
pathomechanism because the transplant kidney is free from podocin mutation and the one 
possibility is the development of autoantibodies against the unmutated protein of the 
transplanted kidney, however, no antipodocin antibodies were detected (38). The alternative 
explanation is the co-presence of circulating PF in affected patients. In these patients good 
effects of plasmapheresis and/or augmented immunosuppressive treatment might support 
the hypothesis that possibly both genetic and endogenous systemic factors play a role in 
recurring pathology. Heterozygous NPHS2 mutation carriers (affected with only one 
NPHS2 mutation) should be distinguished from patients with two pathogenic mutations of 
the NPHS2 gene (homozygous or compound heterozygous mutation carriers); only the 
latter condition fulfill the genetic criteria of autosomal recessive disease. The percentage of 
patients with only one NPHS2 mutation was low (2-3%) given the fact that a second 
mutation has not been missed (38). Some of the homozygous carriers of podocin mutations 
present early recurrence of proteinuria after renal transplantation in association with high 
values of Palb, which suggest a role of PF also in this inherited condition (30). Carraro et al. 
revealed the high pre-transplant Palb activity in 5 children with inherited FSGS due to 
autosomal recessive podocin mutations (17). The post-transplant outcome was complicated 
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in two (with 413G>A mutation) by recurrence of proteinuria after 10 and 300 days with high 
Palb levels at onset that decreased  to reach normal levels in the absence of proteinuria after 
the 7th cycle of PP. Co-incubation of serum with homologous nephrotic urine reduced Palb to 
0, whereas normal urine did not determine any change, which suggest loss of inhibitors in 
nephrotic urine. These data indicate that Palb may be high also in NPHS2 mutated patients, 
probably resulting from loss of inhibitors in urine and lack of correlation of Palb with 
proteinuria suggests a selective loss of inhibitors. In fact, high Palb levels are strongly predictive 
of post-transplant recurrence of FSGS and Palb is removed with ex vivo techniques such as PP 
and immunoabsorption. Loss of inhibitors may play a central role in the process, leading to 
recurrence in the allograft and possibly to proteinuria also in the original disease. (17).  
3.2 Clinical manifestation and risk factors 
Recurrent FSGS presents clinically with proteinuria or even full-blown nephrotic syndrome. 
Although recurrence of FSGS negatively influence kidney allograft survival, it has also been 
noticed that some individuals with proteinuria have adequate kidney function for years. 
Recurrence may be evident within days post-transplant (as early as the first 48 to 72 h), 
particularly in children (29; 38).  Recurrence of FSGS can also develop any time within the 
first two years post-transplant. Multiple risk factors have been associated with recurrence of 
FSGS in the allograft. Children less than 15 years of age (generally between 6 and 15 yr), 
especially Caucasian white have a greater risk of recurrence (up to 40%) than  do adults (36; 
39). An aggressive course of primary FSGS prior to transplant, with a time interval between 
onset of the disease and CKD stage 5 less than 3 years is associated with higher recurrence 
rate (36). Both male gender and high pretransplantation panel-reactive antibodies (PRA) 
levels were noted to be independent risk factors for graft loss from recurrent disease. Also 
patients with mesangial hypercellularity in most of glomeruli as well as fewer sclerotic 
glomeruli have an increased incidence of recurrence (40; 41). Those with collapsing 
histology on native kidneys biopsy, tended to recur with the same histology and the 
presence of collapsing variant in the native kidney biopsy is a risk factor for recurrence (33; 42). 
Patients with history of prior transplant loss secondary to FSGS recurrence have a very high 
risk of recurrence in the current allograft, with rates as high as 80% in the second transplant 
and > 90% in the third and subsequent transplants (36; 43). Some studies have demonstrated 
higher rate of recurrence in recipients of living related grafts; probably due to closer HLA 
matching between living versus deceased donor or the phenotypic characteristics shared by 
related donor-recipient pairs that may render the kidney more susceptible to humoral factors. 
So some centers do not use living related allografts when transplanting particularly children 
(43). The more recent studies do not certify these findings, but with no advantage of graft 
survival in living donor transplants as observed in non-FSGS  patients (44). In general living 
donation kidney transplantation should be avoided for children with FSGS and for adults with 
fulminant FSGS, but in patients not at high risk for recurrent FSGS or if the first graft showed 
prolonged function or was free of FSGS, living donor allografting could be considered, 
provided the fact that donor and recipient have been informed about the risk of disease 
recurrence associated with possible renal graft failure (38). 
3.3 Laboratory and microscopic findings 
There were no significant difference in serum creatinine concentration at the time of 
diagnosis between patients with and without FSGS (45). Proteinuria (at nephrotic range in 
many cases) and lipid levels were significantly greater in patients with FSGS (45).  
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Renal biopsy is often needed for definitive diagnosis, but early biopsies mostly show 
minimal changes on light microscopy. Effacement of foot processes on electron microscopy 
is the initial finding on renal biopsy, appearing within one week of recurrence. Light 
microscopy findings develop several weeks later (46). Hence, during the early post-
transplant period, the diagnosis of FSGS recurrence, while suspected, is difficult to certify. 
Later, biopsies may show evidence of FSGS of the same histological subclass as in native 
kidneys (with 81% conformity) (47). ILPelaar et al. proposed three distinct patterns of 
recurrence: type I with fidelity to native disease (60%), type II with fidelity to native disease 
after a minimal change intermediate (20%), and type III with no fidelity to native disease 
(20%) (47). Arteriolar hyalinosis is more common in patients with FSGS than in patients 
without FSGS but the degree of interstitial fibrosis and tubular atrophy (IF/TA) was not 
significantly different (45). 
4. Treatment of FSGS in kidney allograft recipients 
Treatment strategies for recurrent FSGS are designed to inhibit secretion of the putative 
lymphocyte-derived PF by calcineurin inhibitors and enhance removal of PF by 
plasmapheresis (PP) or combined therapy with PP and cyclophosphamide. Recent reports 
have described the efficacy of anti-CD20 monoclonal antibody, rituximab, in conjunction 
with PP. Other treatments consists with intravenous cyclosporine (CsA) or high dose oral 
steroids. As a symptomatic treatment the use of ACE inhibitors may be recommended. But 
pharmacologic treatment options in recurrent FSGS are limited since most renal transplant 
recipients are already on maintenance steroids plus CsA or Tac, the medications most 
effective in the treatment of idiopathic FSGS as well (48). Because of the increased risk of 
graft loss in renal transplant recipients with FSGS, aggressive therapy should be 
recommended (37). The response of patients to PP seems to be completely individual. About 
50% of patients with recurrent FSGS respond to PP, especially if instituted early in the 
course of disease and before glomerulosclerosis has been established. Individuals who 
develop recurrent FSGS after transplantation usually are given a trial of PP therapy (49). 
Some Centers have added oral Cyclophosphamide (2 mg/kg/day for 2 months) that 
reduces lymphocyte numbers and alters the balance of lymphocyte subsets or 
mycophenolate mofetil (MMF) to the PP protocol (40; 41). Therapeutical success in these 
studies have been variable. The other potentially benefit treatments is immunoadsorption 
with protein A columns followed by IVIG (38). Anti-proteinuric and anti-hypertensive effect 
of agents acting on renin-angiotensin system (ACEI and ARB) in patients with various 
nephropathies has been demonstrated also in recurrent FSGS (50), with 48-31% reduction of 
proteinuria, respectively, but with concern for graft dysfunction if early used post-
transplant. Statins reduce the overall all-case as well as cardio-vascular mortality in post-
transplant patients (51). The lipid-reducing treatment is significantly more common in 
patients with FSGS, and the level of proteinuria correlated significantly with cholesterol and 
TG levels. The use of lipid-lowering agents correlates with better graft prognosis; probably 
these drugs are used more commonly in older renal transplant recipients and with lower 
serum creatinine levels, and these two variables correlate with better graft survival or by 
pleiothropic  effect of HMG-CoA reductase inhibitors on arteriolar endothelium (45). 
Hypercoagulable state is an important modifiable risk factor in NS also in recurrent FSGS. 
The work-up includes measuring of protein C, protein S, and anti-thrombin III levels and 
evaluating for presence of lupus anti-coagulant, anti-phospholipid and anti-cardiolipin 
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antibodies, and for factor V Leiden mutations in the blood. In the presence of evidence for 
thrombophilia, continuous intravenous heparin infusion with a goal to maintain an 
activated partial thromboplastin time (aPTT) of 1,5 times baseline is recommended for the 
immediate post-transplant period (52). Typically i.v. heparin can be switched to s.c. 
enoxaparin after 48 h post-transplant. Argatroban has been used if heparin is 
contraindicated because of the presence of heparin antibodies (52). Long-term anti-
coagulation is need for at least one year post-transplantation and can be achieved with 
warfarin (53). Following transplantation patients with FSGS should be initially monitored 
daily, then weekly for proteinuria with either 24-h urine protein collections or with spot 
urine protein/creatinine ratio. The increase in spot urine protein/creatinine ratio should be 
confirmed by 24-h urine protein collection and followed by kidney biopsy. 
4.1 Plasmapheresis and immunoadsorptive therapies 
Plasmapheresis and Protein A immunoadsorptive therapy have been considered in the 
management of recurrent FSGS because recognizing the role of circulating PF in the 
pathogenesis. With the clinical and experimental evidence, PP as a therapeutic modality 
should be efficient but there are no controlled trials and reports are based on small series of 
patients. Plasmapheresis is most beneficial when used early in the course of recurrent FSGS 
when recurrence occurs early post-transplant (54). Pediatric patients seem to have better 
outcomes in response to PP, with remission rate of 60% to 80% (33; 48). The PP protocols 
varies with number of PP sessions and most patients need between 8 and 12 treatments to 
achieve remission. The good results occurred using a protocol of plasma exchange (1,5 
plasma volumes) for 3 consecutive days followed by every other day for a total of 9 
treatments using 5% albumin replacement. Other typical PP prescription is 1-2 times plasma 
volume exchanges (usually 60 ml for every 1 kg body weight per session)  and about 3-4 
treatments per week until remission is achieved, usually about 10 sessions. Schachter et al. 
found that PP resulted in complete or partial remission in 75% of those with recurrence 
(3/12 complete and 5/12 partial remission; partial remission was defined when proteinuria 
was decreased by 50%) and 25% of patients remained dependent on regular plasma 
exchange to prevent recurrence of proteinuria (55). Prophylactic PP with 8 single-volume 
treatments over 2 weeks prior to transplantation has been attempted in patients at high risk 
for recurrence with variable outcome, in case reports success varied from 50% (56) to less 
significant benefit. Living donor transplant candidates received the first treatment one week 
before transplantation, and deceased donor transplants received the first treatment within 
24 hours of transplant. The preemptive PP, in the week before transplantation, led to 
significant reduction in the rate of recurrence. But in the study of Gonzales et al. the 
preemptive PP (1-10 sessions) did not decrease the rate of recurrence after transplantation 
but was beneficial in treating high-risk patients with documented recurrence, who can 
achieve good graft survival (57). Some centers have added cyclophosphamide and/or 
mycophenolate mofetil (MMF – 2 g/day in two divided doses) to the PP protocol, but with 
variable results (40; 41). In report by Fuentes et al. FSGS recurrence rate was 56.3% after the 
first and 80% in the second transplant in children (33). Plasmapheresis treatment was carried 
out in 7 of 9 patients, achieving remission in six of them. Recurrence of FSGS limited graft 
survival (first year  66% vs 85%, third year 20% vs 68%). The report shows that PP can be 
effective in treating FSGS recurrence in children, although its effect on long-term graft 
survival seems to be more limited (33). Matalon et al. in a group of 13 adult renal transplant 
recipients from 3 transplant centers who underwent PP for recurrent FSGS found 50% or 
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greater decline in proteinuria in 7 of 13 patients, but 3 of them (23%) remained PP-
dependent (and required PP treatments every 2-4 weeks for up to 6 years to prevent 
progressive increase in proteinuria) (48). Five nonresponders progressed to CKD stage 5 
over a mean time of 17 months from the recurrence. The only clinical parameter of 
prognostic significance was a short time interval between recurrence of FSGS and initiation 
of PP (48). Columns coated with staphylococcal protein A are used to treat FSGS because of 
the circulating factor affinity. In one study, patients were treated with protein A 
immunoadsorption columns with significant reduction of proteinuria and the decrease of 
proteinuria was about 82% at the end of the cycle (58). 
4.2 Immunosuppression 
Calcineurin inhibitors: The use of cyclosporine A (CsA) has not reduce the incidence of 
recurrent FSGS, but high doses ameliorate the clinical course of affected patients. There is 
consistent evidence that CsA diminishes or abolishes proteinuria. The exact mechanism of 
CsA in inducing remission is unknown, but immunosuppressive effects of CsA primarily 
result from inhibition of T helper cell activation and inhibition of release of 
cytokines/lymphokines, increase in glomerular cAMP as well as inhibition of glomerular PF 
or non-immunological effect with renal vasoconstriction. High-dose therapy with a goal to 
maintain high trough CsA blood level (recommended 125 to 200 ng/ml) suggest some 
beneficial effects (59). The reason of high whole blood CsA level is to overcome the effect of 
high serum cholesterol level in NS, because CsA is incorporated into the peripheral 
lymphocytes through LDL receptors on the cell surface. High blood level of LDL increase 
the amount of CsA bound to LDL and reduces the cellular uptake of LDL-CsA complex (60). 
In report of Salomon et al. in 14 out of 17 children treated with CsA (3mg/kg/day 
intravenously) for 3 weeks followed by an oral dosage to maintain trough levels between 
200 and 300 ng/ml remission was achieved within 28 days (61). In other report the high-
dose oral CsA (initially from 6 mg/kg/day in two divided doses) was necessary for 
inducting remission with complete and partial remission in 81% of treated patients (62). 
High dose CsA has also been used in connection with PP, but also the success was variable 
(38; 41; 62). Some experience in the treatment of FSGS has been reported with tacrolimus 
(initially at dose 0,15 – 0,1 mg/kg/day in two divided doses) and adjusted to the 
recommended trough blood level (5-10 ng/ml). 
Rituximab: Rituximab is a chimeric mouse/human monoclonal antibody, acting on CD-20 
surface marker of B-lymphocytes with selective depletion of B-lymphocytes. In 
transplantation rituximab is used to treat antibody-mediated rejection. Results of same very 
small cases series of rituximab in post-transplant recurrence of FSGS are inconsistent (63; 
64). The typical regimen is 2-6 doses of 375 mg/m2/dose of rituximab given once every one 
to two weeks. The efficacy of rituximab in recurrent FSGS is limited. The report of 
Rodriguez-Ferrero et al. summarize the effect of rituximab associated with PP treatment of 3 
adult renal transplant recipients with recurrent FSGS after a 4th, a second or a third renal 
transplantation, respectively (65). All the patients were treated with PP once a week after 
recurrence; the first and second patients were treated with PP also before transplantation 
(133 and 62 sessions) to prevent FSGS recurrence. All of the patients received rituximab (375 
mg/m2/wk, 4 doses) and 1 PP session before each rituximab dose. The effectiveness of 
therapy was demonstrated by lack of peripheral CD19 cells after therapy. None of the 
patients treated with rituximab achieved complete remission, but in one patient proteinuria 
was reduced by 26%, in the second by 44% (65). Also Yabu et al. did not observed any 
www.intechopen.com
 
Focal Segmental Glomerulosclerosis (FSGS) Recurrence in Kidney Allograft Recipients 
 
135 
advantage of rituximab therapy. Authors report 4 adult patients (3 women, 1 man; three of 
them received kidney transplant from living-donor) with early recurrent FSGS refractory or 
dependent on PP who received rituximab as sole therapy (total dose 2000 – 4200 mg). None 
of the patients treated with rituximab achieved remission in proteinuria, and one patient 
experienced early graft loss (66). 
Corticosteroids: There are no data or controlled trials on corticosteroid (CS) as a sole 
treatment in recurrent FSGS, because patients are treated with CS in combination with CsA 
and/or PP. The caution is necessary when diminishing CS dosage after kidney 
transplantation in patients with FSGS in native kidneys (67). 
In summary, even though there are no well-conducted studies, aggressive therapy of 
recurrent FSGS using plasmapheresis is considered to be a treatment of choice for this 
condition, with or without high-dose CsA, cyclophosphamide and/or MMF. However, the 
response is completely individual and many patients do not show improvement with any of 
these therapies (49). 
5. Prognosis 
Patients with FSGS often undergo renal transplantation because they are younger and have 
little comorbidity, and they are considered good transplant candidates (68). Unfortunately, 
recurrence of FSGS in the allograft is common. Once the FSGS has recurred in the allograft, 
loss of the graft occurs within 1 year in 50% to 80% of patients who do not receive any extra 
or specific treatment (41). FSGS patients who receive renal transplants have a 2-fold higher 
risk of losing graft at 10 years, compared to all patients transplanted for glomerulonephritis 
(37; 69). In report of Fuentes et al. in pediatric patients with recurrent FSGS graft survival 
was lower than in those with other etiologies of CKD (first year 75% vs 91%; 5th year 44% vs 
78%) (33). In Schachter’s  material recurrence rate was 23% of patients with biopsy proven 
primary FSGS (55). Sener et al. have reported that post-transplant recurrence of FSGS may 
be associated with bilateral nephrectomy indicated in some patients with catastrophic NS 
(70). These patients should be monitored closely for early recurrence and may benefit from 
early PP treatment (70). The type of induction therapy for post-transplant 
immunosuppression is suggestive to have an effect on recurrence of FSGS as well, with 
higher incidence with the use of anti-lymphocyte sera (ALS) or anti-thymocyte globulin 
(ATG) in patients with primary FSGS. The use of ALS or ATG for initial induction therapy 
should be avoided in these patients because of increased recurrence rate of FSGS due to 
induction of certain T-cell subtypes and subsequent lymphokine/cytokine release and 
altering the slit-diaphragm (38). Although CsA seems to have no effect on the frequency of 
FSGS recurrence, there is evidence  that CsA reduces proteinuria and prolongs graft survival 
in patients with recurrence after transplantation. Sirolimus should be used with care 
because of the increased possibility of recurrence (59). Although FSGS previously was 
associated with African-American race white recipients were at greater risk of graft loss 
resulting from recurrent disease. The mechanism of this association in unknown and should 
be investigated further (37). 
The outcome of recurrent FSGS in a transplant kidney is variable, dependent on multiple 
factors and varies from immediate graft loss to slowly progressive proteinuria with chronic 
allograft injury to complete remission with no long-term consequences on the graft. 
Incidence of graft loss in the first 5 years post-transplant, in patients with recurrent FSGS 
varies, and is 20% to 50% (29). The data about the follow-up and outcome are inconsistent, 
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not only in the graft survival rates, but also in risk factors of graft failure. In the report of  
Cosio et al. a significantly greater number of patients with FSGS lost their graft (39%) 
compared with 26% of patients with chronic allograft injury but without FSGS (45). Moroni 
et al. described the quite good outcomes of 52 renal transplants in 47 adults with FSGS (68). 
FSGS recurred in 12 out of 52 grafts (23%) and led to graft failure in 7 within 10 months. In 
the other 5 cases, proteinuria remitted and grafts were functioning 106 months after 
transplantation. The second recurrence developed in 62,5% of re-transplanted patients, who 
lost their first graft because of recurrence, and only one graft was lost. Patients with 
recurrence were more frequently male subjects (83% vs 40%), younger at diagnosis of FSGS 
(16 yr vs 24 yr) and of younger age at transplantation (28 yr vs 36 yr). Graft loss resulting 
from a second recurrence was lower than expected, and treatment with PP (in 
nonresponsive patients), steroids, CsA plus ACE inhibitors achieved either complete or 
partial remission in 80% of the cases (68). 
6. De novo FSGS after kidney transplantation 
De novo FSGS occurs in patients without the diagnosis of FSGS in native kidneys and 
develops more than 6 months posttransplant (45). The pathogenesis for de novo FSGS in 
allografts is unknown but two potential pathogenic mechanisms seem particularly 
attractive: CsA toxicity and hyperfiltration, triggered by hemodynamic stress in remnant 
nephrons following injury to the allograft by rejection or ischemia. In fact, de novo FSGS has 
been reported with sirolimus use (71). Primarily the glomeruli in the outer cortical region 
are involved with occlusive vascular changes and sometimes collapsing glomerulonephritis. 
The histological picture differ from recurrent FSGS, where the mild obliterative 
arteriolopathy preferentially involves the juxtamedullary glomeruli. Clinically, de novo FSGS 
presents with proteinuria and a less aggressive course than recurrent FSGS, but is also a 
negative independent predictor of graft survival. De novo FSGS in renal allografts most often 
is diagnosed in association with chronic allograft nephropathy or recurrent IgA 
nephropathy, transplant glomerulopathy, de novo membranous nephropathy but also may 
be not associated with other pathological conditions (45).  
7. As summary 
Due to increase incidence of FSGS and increasing numbers of FSGS patients coming to 
transplantation, the role of recurrent disease is becoming an area of greater concern to 
nephrologists and transplant physicians. The incidence of recurrence is generally accepted to 
be between 20% to 30%. Risk factors for and characteristics of recurrence include a rapid 
progression of the primary disease to CKD stage 5, early onset of nephrotic range proteinuria 
after allografting, frequent loss of the allograft, a high frequency of recurrence in subsequent 
allografts, and children less than 15 years of age. Some investigators have identified a 
circulating permeability factor, called the FSGS factor, that appears to be protein between 30 
and 50 kD molecular weight. Logically, the association of PF with recurrence of FSGS guided 
to treat patients with plasmapheresis. The response of patients to PP seems to be completely 
individual. Modern immunosuppression regimens including tacrolimus, mycophenolate 
mofetil, sirolimus do not appear to provide additional benefit over older regimens with CsA 
and corticosteroids  in preventing recurrence of FSGS. Patients with recurrence of FSGS clearly 
present a worse outcome than those who do not experience recurrent disease. 
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